Innovative therapeutics

Investors

BioMarin Announces Second Quarter 2014 Financial Results
VIMIZIM® Sales Top $14 million in First Full Quarter of Sales
Full Year Total BioMarin Revenue Guidance Increased
Jul 30, 2014
Financial Highlights ($ in millions, except per share data, unaudited)
             
  Three Months Ended June 30, Six Months Ended June 30,
  2014 2013 % Change 2014 2013 % Change
             
Total BioMarin Revenue  $ 191.7  $ 136.8 40.1%  $ 343.3  $ 264.7 29.7%
VIMIZIM Net Product Revenue  14.3  --     15.2  --   
Naglazyme Net Product Revenue   98.3  69.9 40.6%  178.4  139.3 28.1%
Kuvan Net Product Revenue  46.9  40.9 14.7%  92.1  78.5 17.3%
Aldurazyme Net Product Revenue  24.1  17.5 37.7%  42.2  34.2 23.4%
Aldurazyme Royalty Revenue            
(excluding Net Product Transfer Revenue) - non-GAAP  24.4  21.2 15.1%  46.3  40.5 14.3%
Firdapse Net Product Revenue  4.6  4.1 12.2%  9.3  7.7 20.8%
             
Non-GAAP Net Income (Loss)  $ 10.8  $ --     $ 9.1  $ (8.0)  
Non-GAAP Net Income (Loss) per Share - Basic  $ 0.07  $ --     $ 0.06  $ (0.06)  
Non-GAAP Net Income (Loss) per Share - Diluted  $ 0.06  $ --     $ 0.05  $ (0.06)  
             
GAAP Net Loss   $ (33.5)  $ (21.5)    $ (71.6)  $ (61.3)  
GAAP Net Loss per Share -- Basic  $ (0.23)  $ (0.15)    $ (0.49)  $ (0.46)  
GAAP Net Loss per Share -- Diluted  $ (0.23)  $ (0.16)    $ (0.50)  $ (0.46)  
             
Cash, cash equivalents and investments        $1,080.8  $ 518.5 108.4%
 

SAN RAFAEL, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced financial results for the second quarter ended June 30, 2014.  Non-GAAP net income was $10.8 million, or $0.07 per basic share and $0.06 per diluted share for the second quarter of 2014, compared to non-GAAP net loss of $0.0 million for the second quarter of 2013. Non-GAAP net income was $9.1 million, or $0.06 per basic share and $0.05 per diluted share for the six months ended June 30, 2014, compared to a loss of ($8.0) million, or ($0.06) per basic and diluted share for the six months ended June 30, 2013.

GAAP net loss was ($33.5) million, or ($0.23) per basic and diluted share for the second quarter of 2014, compared to GAAP net loss of ($21.5) million, or ($0.15) per basic share and ($0.16) per diluted share for the second quarter of 2013. GAAP net loss for the six months ended June 30, 2014 was ($71.6) million, or ($0.49) per basic share and ($0.50) per diluted share, as compared to GAAP net loss of ($61.3) million, or ($0.46) per basic and diluted share for the six months ended June 30, 2013.

The increased non-GAAP net income for the second quarter of 2014 compared to the second quarter of 2013 was primarily due to strong uptake of VIMIZIM® in its first full quarter of commercial sales, and significant growth in revenues from our other commercial products including, Naglazyme®, KUVAN®, Aldurazyme® and Firdapse®. Naglazyme revenue growth of 41% in the quarter compared to the prior year reflected both continued growth in number of patients consistent with long term trends, and also included significant purchases from certain governmental entities which potentially reflects patient demand in future quarters. These revenue increases were partially offset by increased research and development expenses for PEG PAL, BMN 190 and BMN 673, as well as increased selling, general and administrative expenses related to VIMIZIM launch activities.  Increased GAAP net loss was also driven by increased income tax expense and interest expense in the second quarter. These measures are excluded from the non-GAAP measurements.   As of June 30, 2014, BioMarin had cash, cash equivalents and investments totaling $1,080.8 million, as compared to $518.5 million on June 30, 2013. 

"With the strong launch of VIMIZIM and continued double-digit year over year growth of our other products, we believe the ultra-orphan business model is as robust as ever. We are extremely pleased with the momentum of the U.S. commercial launch of VIMIZIM.  At the end of the second quarter, 132 patients had started receiving commercial VIMIZIM," said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. "Since receiving approval of VIMIZIM in the European Union in April, we are making good progress seeking reimbursement on a country by country basis. The excitement we are seeing in the Morquio community is driving our expectation of continued, rapid uptake of VIMIZIM across all our commercial markets. With E.U. approval in hand, we believe VIMIZIM sales combined with the strength of our other marketed products will help BioMarin reach over $1 billion in revenues over the next 2-3 years."  

Net Product Revenue (unaudited)

Total Revenue Growth (in millions)
  Three Months Ended June 30, Six Months Ended June 30,
  2014 2013 $ Change % Change  2014 2013 $ Change % Change 
                 
VIMIZIM  $ 14.3  $ --   $ 14.3 --  $ 15.2 $ --   $ 15.2 --
Naglazyme (1)  98.3  69.9  28.4 40.6%  178.4  139.3  39.1 28.1%
Kuvan  46.9  40.9  6.0 14.7%  92.1  78.5  13.6 17.3%
Aldurazyme  24.1  17.5  6.6 37.7%  42.2  34.2  8.0 23.4%
Firdapse  4.6  4.1  0.5 12.2%  9.3  7.7  1.6 20.8%
Net product revenue  188.2  132.4  55.8 42.1%  337.2  259.7  77.5 29.8%
                 
Collaborative agreement revenue  0.5  0.9  (0.4)    0.9  1.0  (0.1)  
Royalty and license revenue  3.0  3.5  (0.5)    5.2  4.0  1.2  
Total BioMarin revenue - GAAP  191.7  136.8  54.9 40.1%  343.3  264.7  78.6 29.7%
                 
Less: Previously recognized Aldurazyme net product transfer revenue  (0.3)  (3.7)  3.4    (4.1)  (6.3)  2.2  
Total BioMarin revenues (excluding Aldurazyme net product transfer revenue) - Non-GAAP (2)  $ 192.0  $ 140.5  $ 51.5 36.7%  $ 347.4  $ 271.0  $ 76.4 28.2%
                 
                 
Reconciliation of Aldurazyme Revenues (in millions)
  Three Months Ended June 30, Six Months Ended June 30,
  2014 2013 $ Change % Change  2014 2013 $ Change % Change 
Aldurazyme revenue reported by Genzyme  $ 62.3  $ 53.6  $ 8.7 16.2%  $ 118.2  $ 102.1  $ 16.1 15.8%
                 
  Three Months Ended June 30,   Six Months Ended June 30,  
  2014 2013 $ Change   2014 2013 $ Change  
Aldurazyme Royalties due from Genzyme - Non-GAAP (2)  $ 24.4  $ 21.2  $ 3.2    $ 46.3  $ 40.5  $ 5.8  
Previously recognized net product transfer revenue (3)  (0.3)  (3.7)  3.4    (4.1)  (6.3)  2.2  
Total Aldurazyme net product revenue - GAAP  $ 24.1  $ 17.5  $ 6.6    $ 42.2  $ 34.2  $ 8.0  
                 
(1) Naglazyme revenues experience quarterly fluctuations due to the timing of government ordering patterns in certain countries. The Company does not believe these fluctuations reflect a change in underlying demand.
(2) BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the end-user demand for Aldurazyme. The Aldurazyme net product transfer revenue is the result of timing of deliveries to Genzyme Corp. and is therefore not representative of patient demand for the product. By providing information about both the GAAP and non-GAAP revenue measures, the Company believes that the additional information enhances investors' overall understanding of the Company's business and in particular allows for more consistent period to period evaluation of the revenue.
(3) To the extent units shipped to third party customers by Genzyme exceed BioMarin inventory transfers to Genzyme, BioMarin will record a decrease in net product revenue from the royalty payable to BioMarin for the amount of previously recognized product transfer revenue. If BioMarin inventory transfers exceed units shipped to third party customers by Genzyme, BioMarin will record incremental net product transfer revenue for the period. 
 

Priority Review Voucher Sold for $67.5 million

The Company also announced today that it had sold the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in February of this year. The Company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of VIMIZIM®, a new biological product for patients with Mucopolysaccharidosis type IVA, also known as Morquio A syndrome. BioMarin received $67.5 million from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., in exchange for the voucher.

Updated 2014 Guidance, as of July 30, 2014  

Revenue Guidance 
($ in millions)
  Initially Provided Updated
Item  February 26, 2014 July 30, 2014
Total BioMarin Revenues $650 to $680 $745 to $765*
Naglazyme Net Product Revenue $290 to $310 $305 to $320
Kuvan Net Product Revenue $180 to $200  $180 to $200 
VIMIZIM $60 to $70 $60 to $70
* Includes of $67.5 million for the sale of the Priority Review Voucher.
     
Selected Income Statement Guidance 
($ in millions, except percentages)
  Initially Provided Updated
Item  February 26, 2014 July 30, 2014
Cost of Sales (% of Total Revenue) 17.5% to 18.5% 16.5% to 17.5%
Research and Development Expense $500 to $530 $460 to $480
Selling, General and Admin. Expense $265 to $285 $280 to $295
GAAP Net Loss $(255) to $(285) $(180) to $(195)*
Non-GAAP Net Loss $(100) to $(130) $(60) to $(80)
* Includes $50 million net of taxes, related to the sale of the Priority Review Voucher.
 

Anticipated Upcoming Milestones

4Q 2014: Enrollment completion of Phase 1/2 trial with BMN 190 for the treatment of Batten disease
1Q 2015: IND filing or equivalent for BMN 270 for the treatment of Hemophilia A
2Q 2015: Data on first three cohorts in Phase 2 with BMN 111 for the treatment of Achondroplasia
1H 2015: Enrollment completion of Phase 2/3 trial with BMN 701 for the treatment of Pompe disease
2H 2015: Results from Phase 1/2 trial with BMN 190 for the treatment of Batten disease
2H 2015: Enrollment completion of Phase 3 trial with talazoparib (BMN 673) for the treatment of mBC
Mid-2015: IND filing or equivalent for BMN 250 for the treatment of MPS IIIB
4Q 2015: Results from pivotal Phase 3 trial with PEG PAL for the treatment of PKU
1Q 2016: Submission of PEG PAL BLA to the FDA for the treatment of PKU
 

Commercial and Regulatory Update on VIMIZIM for Mucopolysaccharidosis type IVA

  • E.U.: On April 28, 2014 the European Commission granted marketing authorization for VIMIZIM, the first specific treatment approved in the European Union (E.U.) for Mucopolysaccharidosis type IVA in patients of all ages. As the first drug ever approved for Morquio A syndrome, VIMIZIM has been granted orphan drug status in the E.U., which confers ten years of market exclusivity. The commercial launch of VIMIZIM in the E.U. is underway.

Advanced Clinical Programs

  • Phase 3 with PEG PAL for PKU: The Company expects top-line results from this study in 4Q15. Patients enrolling in the BMN 165-302 Phase 3 study will need to demonstrate a pre-specified reduction in blood Phe prior to entering the trial. The design includes: (1) an open-label study to evaluate safety and blood Phe levels in naïve patients; and, (2) a randomized controlled study of the open-label study patients who meet the pre-specified eligibility criteria to evaluate blood Phe levels and neurocognitive endpoints.
     
  • BioMarin was Issued the International Nonproprietary Name (INN) Talazoparib for its Oncology Product, BMN 673.  The World Health Organization (WHO) has approved the INN "talazoparib" (pronounced ta-la-ZO-parib) for the Company's poly ADP-ribose polymerase (PARP) inhibitor to treat genetically defined cancers.

Phase 3 with talazoparib (BMN 673) for gBRCA breast cancer: The Company is conducting a Phase 3 trial to study talazoparib for the treatment of deleterious germline BRCA mutation metastatic breast cancer and is currently enrolling patients. The Phase 3 trial is an open-label, 2:1 randomized, parallel, two-arm study of talazoparib as compared to monotherapy of physicians' choice (capecitabine, eribulin, gemcitabine or vinorelbine) in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer who have received no more than two prior chemotherapy regimens for metastatic disease. The global study will enroll approximately 429 subjects. The primary objective of the study is to compare progression-free survival (PFS) of subjects treated with talazoparib as a monotherapy relative to those treated with protocol-specific physicians' choice. 

  • Phase 2/3 with BMN 701 for Pompe Disease: In May 2014, the Company announced that it had dosed the first patient in the Phase 3 INSPIRE trial with BMN 701, GILT-tagged Recombinant Human GAA, for the treatment of Pompe disease. This single-arm Phase 2/3 trial is enrolling patients previously treated with alglucosidase alfa and switching them to a treatment of BMN 701 at 20 mg/kg administered every other week for 24 weeks. The primary endpoint of the study will be change from baseline in the respiratory parameter Maximal Inspiratory Pressure (MIP). 
     
  • Phase 2 with BMN 111 for Achondroplasia: In the first quarter of 2014, the Company announced that it had dosed the first child in the Phase 2 trial with BMN 111, an analog of C-type Natriuretic Peptide (CNP), for the treatment of children with achondroplasia. Achondroplasia is the most common form of disproportionate short stature or dwarfism. The Phase 2 study is an open-label, sequential cohort, dose-escalation study of BMN 111 in children who are 5-14 years old. The primary objective of this study is to assess the safety and tolerability of daily subcutaneous doses of BMN 111 administered for 6 months. Prior to enrolling in the Phase 2 study, all patients will have participated in a 6 month natural history study to determine baseline growth velocity data.

Early-stage Clinical Programs

  • BMN 190 for LINCL (Batten disease): The Company is conducting a Phase 1/2 trial with BMN 190, a recombinant human tripeptidyl peptidase 1 (rhTPP1), for the treatment of patients with late-infantile neuronal ceroid lipofuscinosis type 2 (NCL-2), a form of Batten disease. This is the first time that patients with Batten Disease have been treated with an enzyme replacement therapy in a clinical trial setting. The Phase 1/2 study is an open-label, dose-escalation study in patients with NCL-2. The primary objectives are to evaluate the safety and tolerability of BMN 190 and to evaluate effectiveness using an NCL-2-specific rating scale score in comparison with natural history data after 48 weeks of treatment. Secondary objectives are to evaluate the impact of treatment on brain atrophy in comparison with NCL-2 natural history after 48 weeks of treatment and to characterize pharmacokinetics and immunogenicity. The study will enroll approximately 22 subjects for a treatment duration of 48 weeks.

Preclinical Programs

  • BMN 270 for Hemophilia A: In January 2014, the Company announced that it had selected an AAV-factor VIII gene therapy drug candidate, BMN 270, to develop for the treatment of hemophilia A and has initiated IND-enabling studies.
     
  • BMN 250 for MPS IIIB: In February 2014, the Company announced that it had selected an BMN 250, an intracerebroventricular enzyme replacement therapy, for the treatment of Mucopolysaccharidosis IIIB (MPS IIIB) or Sanfilippo Syndrome Type B (Sanfilippo B). BioMarin has initiated IND-enabling studies.

Non-GAAP Net Income (Loss) and Reconciliation

The results for the three and six months ended June 30, 2014 and June 30, 2013 and the guidance for 2014 include both GAAP net loss and non-GAAP net income/loss. As used in this release, non-GAAP net income/loss is based on GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) and further adjusted to exclude certain non-cash stock compensation expense, non-cash contingent consideration expense and certain other nonrecurring material items (non-GAAP net income/loss). 

The following table presents the reconciliation of GAAP to non-GAAP financial metrics:

Reconciliation of GAAP Net Loss to Non-GAAP Net Income (Loss)
(in millions)
(unaudited) 
 
  Three Months Ended
June 30, 
Six Months Ended
June 30, 
Year Ending
December 31,
  2014 2013 2014 2013 2014 Guidance
           
GAAP Net Loss  $ (33.5)  $ (21.5)  $ (71.6)  $ (61.3)  $(180.0) - $(195.0) 
           
Interest expense, net  7.5  --   15.5  1.0  31.3 
Provision for (benefit from) income taxes   5.8  1.2  9.3  (3.5)  14.5 - 19.5 
Depreciation expense  8.0  6.6  14.6  12.7  32.0 
Amortization expense  2.9  3.6  5.5  6.2  11.1 
EBITDA Loss  (9.3)  (10.1)  (26.7)  (44.9)  (86.1) - (106.1) 
           
Stock-based compensation expense  17.3  13.9  33.6  25.5  84.6 
Contingent consideration expense (1)  2.6  (3.8)  10.8  1.0  17.6 
Non-recurring:          
Sale of Priority Review Voucher (4)          (67.5) 
Gain on termination of lease (2)  (0.5)  --   (9.3)  --   (9.3) 
Debt conversion expense (3)  0.7  --   0.7  10.4  0.7 
Non-GAAP Net Income (Loss)  $ 10.8  $ --   $ 9.1  $ (8.0)  $(60.0) - $(80.0) 
           
(1) Represents the expense associated with the change in the fair value of contingent acquisition consideration payable for the period, resulting from changes in estimated probabilities and timing of achieving certain developmental milestones.
(2) Represents the net gain due to the early termination of the Company's operating lease and the realization of the remaining balance in deferred rent upon acquisition of the San Rafael Corporate Center where the Company's corporate headquarters are located, as well as other facilities the Company has acquired that were previously under operating lease.
(3) Represents debt conversion expense associated with the early conversion of a portion of our 2017 convertible notes.
(4) Represents the total sales price of $67.5 million for the PRV, or approximately $50.0 million net of tax.
 

BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, VIMIZIM, Naglazyme, Kuvan, Aldurazyme and Firdapse, and development of the Company's pipeline. By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the Company believes that the additional information enhances investors' overall understanding of the Company's business and prospects for the future. Further, the Company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.

Conference Call Details

BioMarin will host a conference call and webcast to discuss second quarter 2014 financial results today, Wednesday, July 30, at 4:30 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.BMRN.com.

U.S. / Canada Dial-in Number: 877.303.6313
International Dial-in Number: 631.813.4734
Conference ID: 59207209
 
Replay Dial-in Number: 855.859.2056
Replay International Dial-in Number: 404.537.3406
Conference ID: 59207209
 

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products include: Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Powder for Oral Solution and Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; Firdapse® (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS); and VIMIZIM® (elosulfase alfa) for the treatment of Morquio A (MPS IVA). Product candidates include: BMN 165 (PEGylated recombinant phenylalanine ammonia lyase), also referred to as PEG PAL, which is currently in Phase 3 clinical development for the treatment of PKU; talazoparib (BMN 673), a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 3 clinical development for the treatment of germline BRCA breast cancer; BMN 701, a novel fusion of acid alpha glucosidase (GAA) with a peptide derived from insulin like growth factor 2, which is currently in Phase 3 clinical development for the treatment of Pompe disease; BMN 111, a modified C-natriuretic peptide, which is currently in Phase 2 clinical development for the treatment of achondroplasia; and BMN 190, a recombinant human tripeptidyl peptidase-1 (rhTPP1), which is currently in Phase 1 for the treatment of late-infantile neuronal ceroid lipofuscinosis (CLN2), a form of Batten Disease. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to VIMIZIM, Naglazyme, Kuvan, Aldurazyme and Firdapse; the financial performance of BioMarin as a whole; the timing of BioMarin's clinical trials of PEG PAL, talazoparib (BMN 673), BMN 701, BMN 111, BMN 190, BMN 270, BMN 250 and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, Firdapse, VIMIZIM and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the commercialization of VIMIZIM, Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to PEG PAL, talazoparib (BMN 673), BMN 701, BMN 111 and BMN 190; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan, VIMIZIM and Firdapse; actual sales of Aldurazyme, Naglazyme, Kuvan, VIMIZIM and Firdapse; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the risk factors contained under the caption "Risk Factors" in BioMarin's 2013 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, VIMIZIM®, Naglazyme®, Kuvan®, and Firdapse® are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

BIOMARIN PHARMACEUTICAL INC.
     
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, 2014 and December 31, 2013
(In thousands of U.S. dollars, except share and per share amounts)
     
     
  June 30,
2014
December 31,
2013(1)
ASSETS  (unaudited)  
Current assets:    
Cash and cash equivalents  $ 584,717  $ 568,781
Short-term investments  251,901  215,942
Accounts receivable, net (allowance for doubtful accounts: $568 and $529, respectively)  122,282  117,822
Inventory  193,498  162,605
Current deferred tax assets  30,561  30,561
Other current assets  37,268  41,707
 Total current assets  1,220,227  1,137,418
Noncurrent assets:    
Investment in BioMarin/Genzyme LLC  440  816
Long-term investments  244,148  267,700
Property, plant and equipment, net  469,862  319,316
Intangible assets, net  163,045  163,147
Goodwill  54,258  54,258
Long-term deferred tax assets  147,143  145,234
Other assets  46,562  156,171
 Total assets  $ 2,345,685  $ 2,244,060
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current liabilities:    
Accounts payable and accrued liabilities  $ 166,720  $ 183,271
Total current liabilities  166,720  183,271
Noncurrent liabilities:    
Long-term convertible debt  650,872  655,566
Long-term contingent acquisition consideration payable  40,466  30,790
Other long-term liabilities  25,658  33,392
Total liabilities  883,716  903,019
Stockholders' equity:    
Common stock, $0.001 par value: 250,000,000 shares authorized at June 30, 2014 and December 31, 2013; 147,067,950 and 143,463,668 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively.  147  144
Additional paid-in capital  2,249,445  2,059,101
Company common stock held by Nonqualified Deferred Compensation Plan  (10,146)  (7,421)
Accumulated other comprehensive income  9,941  5,018
Accumulated deficit  (787,418)  (715,801)
Total stockholders' equity  1,461,969  1,341,041
Total liabilities and stockholders' equity  $ 2,345,685  $ 2,244,060
     
(1) December 31, 2013 balances were derived from the audited consolidated financial statements.
 
 
BIOMARIN PHARMACEUTICAL INC.
         
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Three and Six Months Ended June 30, 2014 and 2013
(In thousands of U.S. dollars, except per share amounts)
(Unaudited) 
         
  Three Months Ended
June 30,
Six Months Ended
June 30, 
  2014 2013 2014 2013
REVENUES:        
Net product revenues  $ 188,244  $ 132,400  $ 337,248  $ 259,744
Collaborative agreement revenues  506  889  921  1,024
Royalty, license and other revenues  3,037  3,521  5,170  3,970
Total revenues  191,787  136,810  343,339  264,738
OPERATING EXPENSES:        
Cost of sales (excludes amortization of certain acquired intangible assets)  31,210  22,567  54,026  43,067
Research and development  107,702  85,661  193,868  169,404
Selling, general and administrative  68,089  50,656  128,158  101,706
Intangible asset amortization and contingent consideration  3,668  (2,022)  12,625  3,534
Total operating expenses  210,669  156,862  388,677  317,711
LOSS FROM OPERATIONS  (18,882)  (20,052)  (45,338)  (52,973)
Equity in the loss of BioMarin/Genzyme LLC  (539)  (163)  (877)  (564)
Interest income  1,735  650  2,858  1,368
Interest expense  (9,221)  (603)  (18,327)  (2,328)
Debt conversion expense  (674)  --   (674)  (10,420)
Other income (expense)  (147)  (123)  6  105
LOSS BEFORE INCOME TAXES  (27,728)  (20,291)  (62,352)  (64,812)
Provision for (benefit from) income taxes  5,774  1,242  9,265  (3,469)
NET LOSS  $ (33,502)  $ (21,533)  $ (71,617)  $ (61,343)
NET LOSS PER SHARE, BASIC  $ (0.23)  $ (0.15)  $ (0.49)  $ (0.46)
NET LOSS PER SHARE, DILUTED  $ (0.23)  $ (0.16)  $ (0.50)  $ (0.46)
         
Weighted average common shares outstanding, basic 146,120 139,400 145,066 133,716
Weighted average common shares outstanding, diluted 146,351 139,596 145,297 133,716
         
COMPREHENSIVE LOSS   $ (30,836)  $ (20,247)  $ (66,694)  $ (58,700)
         
         
STOCK-BASED COMPENSATION EXPENSE
Total stock-based compensation expense included in the Condensed Consolidated Statements of Comprehensive Loss was as follows
(unaudited):
  Three Months Ended
June 30,
Six Months Ended
June 30, 
  2014 2013 2014 2013
         
Cost of sales  $ 1,640  $ 1,130  $ 2,726  $ 2,174
Research and development  6,894  6,381  14,009  11,705
Selling, general and administrative  8,716  6,418  16,820  11,615
   $ 17,250  $ 13,929  $ 33,555  $ 25,494
 
CONTACT: Investors:

         Traci McCarty

         BioMarin Pharmaceutical Inc.

         (415) 455-7558



         Media:

         Debra Charlesworth

         BioMarin Pharmaceutical Inc.

         (415) 455-7451

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information